Fortress Biotech (FBIO) Q4 2025 earnings summary

Executive summary

• Net revenue increased 10% year-over-year to $63.3 million, driven by the launch of Emrosi and milestone/royalty income from asset sales and partnerships.

• Operating loss narrowed to $70.2 million from $110.4 million in 2024, reflecting lower R&D and asset impairment expenses.

• Significant asset monetizations included the $205 million sale of a priority review voucher and the $28 million sale of a subsidiary.

• Cash and cash equivalents at year-end were $79.4 million, with additional liquidity from asset sales and equity offerings.

Financial highlights

• Net revenue: $63.3 million in 2025 vs. $57.7 million in 2024 (+10%).

• Product revenue from Journey: $61.2 million in 2025 (+11% YoY), with Emrosi contributing $14.7 million.

• Operating expenses decreased 21% to $133.5 million, mainly due to a 79% reduction in R&D expenses.

• Net income attributable to the company was $6.8 million, compared to a net loss of $46.0 million in 2024.

• Cash flow from operations improved by $14.4 million year-over-year.

Outlook and guidance

• Management expects R&D and SG&A expenses to increase or remain flat in 2026, with new in-licenses and product launches anticipated.

• Current cash and equivalents are expected to fund operations for at least the next 12 months; additional financing may be required for future growth.